Navigation Links
Oncology National Commercial (ONC) Study Outlines 10 Trends Shaping the Market for Oncology Pharmaceutical and Biotech Products

RALEIGH, N.C., May 31, 2011 /PRNewswire/ -- Today, Campbell Alliance released the results of its Oncology National Commercial (ONC) Study, the latest in its Landmark Study series.  A summary report of the study's findings is available at, and the firm is sharing a more in-depth presentation of the results with its clients by request.

The ONC Study explores the factors that have caused major changes in the oncology market over the past 10 years and evaluates how those factors will continue to shape the market during the next decade.  It also provides recommendations on how pharmaceutical and biotech companies should manage the increasingly challenging oncology market environment.

To gather information for the study, Campbell Alliance interviewed decision makers from 9 of the world's top-20 pharmaceutical and biotech companies, a range of national and regional payer organizations, and several integrated delivery systems, as well as 10 oncology key opinion leaders and 20 community hematologists/oncologists.

According to Jeff Stewart, one of the study's authors, "We felt it was the right time to document how much oncology has changed over the past decade and take a look forward.  In truth, the extent of change has been breathtaking.  New therapies are only the beginning of the story.  Oncologists have changed.  Payers have changed.  Sales forces have changed.  Medicare has changed.  Financial incentives have changed, and patients have changed.  It's a different world, and it continues to evolve."

The study outlined 10 key trends that will shape the market for years to come.  Five of the trends relate to product development, while the other five relate to commercial issues.  The study's report indicates that these trends—when their effects are combined—are bringing about a "perfect storm" in oncology that will make the environment far more challenging for pharmaceutical and biotech firms.  According to the report's authors, the study's objective is to help industry decision makers understand the drivers of change within their environment and begin developing strategies that will help their companies thrive in a market that will only get more challenging over the next few years.

About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry.  The firm's clients include most of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms.  Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Managed Markets, Medical Affairs, and Sales.  From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan.

For Campbell Alliance:
James Forte
Campbell Alliance
919-844-7100 ext. 7195

SOURCE Campbell Alliance
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Beardsworth Continues to Strengthen Oncology Operations
4. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
5. Caliper Announces New Oncology Research Collaboration
6. Champions Biotechnology Changes Name to Champions Oncology
7. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
8. Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development
9. D3 Oncology Solutions Now Includes Via Oncology Pathways for Medical Oncology
10. Georgia Health Sciences University Clinical Study Shows RyMed InVision-Plus® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
11. DiaTech Oncology and Walter Reed Army Medical Center Establish Pilot to Determine Best Chemotherapy for Cancer Patients
Post Your Comments:
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
Breaking Biology Technology:
(Date:11/20/2015)... OXFORD, Connecticut , November 20, 2015 ... biometric authentication company focused on the growing mobile commerce ... its CEO, Gino Pereira , was recently interviewed ... The interview will air on this weekend on ... Bloomberg Latin America . --> NXTD ) ...
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
(Date:11/12/2015)...  A golden retriever that stayed healthy despite having ... provided a new lead for treating this muscle-wasting disorder, ... of MIT and Harvard and the University of São ... Cell, pinpoints a protective gene that boosts ... The Boston Children,s lab of Lou Kunkel , ...
Breaking Biology News(10 mins):